<DOC>
	<DOCNO>NCT01194960</DOCNO>
	<brief_summary>Based pre-clinical clinical data , may advantageous administer cancer vaccine chemotherapy enhance immune response , thus lead effective therapeutic approach subject metastatic HRPC . This clinical study evaluate role combination therapy TroVax® plus Docetaxel vs. Docetaxel alone progression free survival ( PFS ) subject HRPC .</brief_summary>
	<brief_title>TroVax® In Subjects With Hormone Refractory Prostate Cancer ( HRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Signed &amp; date write informed consent obtain subject accordance w/local regulation . 2 . Histologically confirm conventional and/or mucinous adenocarcinoma prostate . If histological confirmation available , cytological confirmation permit lieu . 3 . Must meet one follow 3 criterion progressive disease follow androgen deprivation : A . Subjects w/nodal visceral metastasis : Must progressive disease define RECIST criterion define Prostate Cancer Clinical Trials Working Group II ( Scher et al . 2008 ) . B . Subjects w/no measurable disease : PSA disease must elevate PSA define Consensus Criteria Prostate Cancer Clinical Trials Working Group II ( Scher et al . 2008 ) . PSA must indicate progressive disease define rise PSA value , least 7 day apart , &gt; 2 ng/mL 28 day prior randomization . C. Subjects w/bone involvement : New disease bone scan define Consensus Criteria Prostate Cancer Clinical Trials Working Group II ( Scher et al . 2008 ) . 4 . Subjects stable dose bisphosphonates show subsequent tumor progression may continue medication ; however , subject allow initiate bisphosphonate therapy w/in 28 day prior start study treatment Week 1 time study , 5 . Must clinically immunocompetent . Clinical immunocompetence assume unless subject diagnose immunosuppressed , receive immunosuppressive chemotherapy oncology disorder , receive immunosuppressive therapy follow transplant , case exclude . 6 . Subject free clinically apparent/active autoimmune disease ( prior confirm diagnosis treatment autoimmune disease include Systemic Lupus Erythematosis , Grave 's Disease , Hashimoto 's Thyroiditis , Multiple Sclerosis , &amp; Rheumatoid Arthritis ) . 7 . Subject adequate bone marrow function define Absolute Lymphocyte Count ( ALC ) ≥ 500/µL , Absolute Neutrophil Count ( ANC ) &gt; 1200/µL , Platelet Count &gt; 100,000/µL . 8 . Subject peripheral neuropathy grade ≤1 . 9 . Subject ECOG status 0 1 . 10 . Minimum life expectancy ≥6 month . 11 . Progressive disease ( define ) must document discontinuation hormonal antiandrogen therapy . 12 . Subject continue stay medical treatment LHRH agonists LHRH antagonist maintain testosterone value &lt; 50ng/dL . EXCLUSION CRITERIA : 1 . Subject receive prior chemotherapy prostate cancer time . Subject receive chemotherapy reason within five year screen . 2 . Subject receive hormonal therapy , include dose Megestrol Acetate , Finasteride , herbal product know decrease PSA level ( e.g. , Saw Palmetto &amp; PCSPES ) , systemic corticosteroid must discontinue agent least 4 week prior anticipate Week 1 visit . LHRH agonists LHRH antagonist need discontinue . 3 . Subject start bisphosphonate denosumab therapy le 28 day anticipate Week 1 visit . 4 . Subject use supplement complementary medicines/botanicals . Subjects review label w/their doctor prior enrolment . Exceptions exclusion : Conventional multivitamin supplement Selenium Lycopene Soy supplement Vitamin E Fish oil supplement Vitamin D Glucosamine supplement Agerelated eye disease vitamins Ginkgo biloba 5 . Subject major surgery radiation therapy complete &lt; 4 week prior screen . 6 . Corticosteroids permit except ( ) nasal spray inhaler , ( b ) orally prescribed replacement therapy case adrenal insufficiency , ( c ) oral IV dexamethasone administration use acutely combination docetaxel , ( ) parenteral use single occasion , ( e ) low dose parenteral use maximum 5 day ( f ) acute sporadic parenteral use acute asthma . 7 . Subject known test positive HIV hepatitis B C. 8 . Subject receive concurrent chemotherapy , immunotherapy , radiotherapy investigational agent . 9 . Subject Platelet count &gt; 400,000/μL ; Monocytes &gt; 80,000/μL ; Haemoglobin &lt; 11g/dL . 10 . Subject cerebral metastasis ( know previous investigation clinically detectable ) . 11 . Subject serum testosterone &gt; 50ng/dL . 12 . Subject rheumatoid disease ( asymptomatic subject w/controlled &amp; rarely flaring rheumatoid arthritis also exclude ) . 13 . Subject exhibit evidence symptomatic congestive heart failure , pulmonary embolus , vascular thrombosis , transient ischemic attack , cerebrovascular accident , unstable angina , myocardial infarction active ischemia ECG . If ECG take prior screen within 28 day anticipate Week 1 visit available , ECG must perform screening . 14 . Subject uncontrolled severe hypertension &gt; 150/100mm Hg ( control w/medication exclusion ) . 15 . Subject hypotensive .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>cancer prostate</keyword>
	<keyword>cancer prostate</keyword>
	<keyword>neoplasm prostate</keyword>
	<keyword>neoplasm prostatic</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>prostate neoplasm</keyword>
	<keyword>prostatic cancer</keyword>
	<keyword>prostate specific antigen</keyword>
	<keyword>prostatic hyperplasia</keyword>
</DOC>